ReviewNanomedicine (London, England)2014
Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung.
Review in Nanomedicine (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy.ACS nano medicine · 2026Article
- Productivity Improvement of Human Papillomavirus-like Particles in Insect Cells Using Hyper-Expression Baculovirus Vector.Vaccines · 2025Article
- STING Agonist-Loaded Physalis Mottle Virus-like Particles as a Potent Prophylactic for Metastatic Melanoma.ACS applied materials & interfaces · 2025Article
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Nano-Particulate Platforms for Vaccine Delivery to Enhance Antigen-Specific CD8Methods in molecular biology (Clifton, N.J.) · 2022Article
- Peptide-based supramolecular vaccine systems.Acta biomaterialia · 2021Review
- Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.Biotechnology reports (Amsterdam, Netherlands) · 2021Review
- Recent Development of Ruminant Vaccine Against Viral Diseases.Frontiers in veterinary science · 2021Review
- SARS-CoV-2 reinfection and implications for vaccine development.Human vaccines & immunotherapeutics · 2020Review
- A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.Journal of virology · 2020Article
- Computational tools for modern vaccine development.Human vaccines & immunotherapeutics · 2020Review
- Virus-like particles for vaccination against cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.NPJ vaccines · 2019Article
- Eliminating Factor H-Binding Activity ofFrontiers in immunology · 2018Article
- Sortase-Mediated Ligation as a Modular Approach for the Covalent Attachment of Proteins to the Exterior of the Bacteriophage P22 Virus-like Particle.Bioconjugate chemistry · 2017Article
- Article
- In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer.Nature nanotechnology · 2016Article
- Phase separation in biology; functional organization of a higher order.Cell communication and signaling : CCS · 2016Review
- Virus-Based Nanoparticles as Versatile Nanomachines.Annual review of virology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The lung is a major entry point for many of the most detrimental pathogens to human health. The onslaught of pathogens encountered by the lung is counteracted by protective immune responses that are generated locally, which can be stimulated through vaccine strategies to prevent pathogen infections. Here, we discuss the use of virus-like particles (VLPs), nonpathogen derivatives of viruses or protein cage structures, to construct new vaccines exploiting the lung as a site for immunostimulation. VLPs are unique in their ability to be engineered with near molecular level detail and knowledge of their composition and structure. A summary of research in developing VLP-based vaccines for the lung is presented that suggests promising results for future vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.